31. Influence of hydralazine on interstitial fluid pressure in experimental tumors - a preliminary study : Vpliv hydralazina na tlak medcelične tekočine v poskusnih tumorjihBlaž Podobnik, Damijan Miklavčič, 2000, original scientific article Abstract: Background. Interstitial fluid pressure (IFP) has been recognised as the most important obstacle in macromolecular drug delivery to solid tumors. Our interest was to reduce differentialy tumor IFP with respect to IFP in surrounding and normal tissues in order to increase drug delivery to tumors aswell to increase tumor blood flow and potentialy tumor tissue oxygenation. In this preliminary study we used hydralazine, a longacting arterial vasodilator. Materials and methods. Measurements of interstitial fluid pressure were performed in vivo on CBA mice bearing SAF tumors using wick-in-needle technigue. Altogether eleven measurements were obtained on different animals with tumors of different size. Results. IFP in tumors after hydralazine administration was significantly lower than initial values in corresponding tumors. On average tumor IFP decreased for 33 % from initial value. On the contrary, no change in IFP in normal tissue was observed after hydralazine administration. Also, after injection of physiological saline instead of hydralazine there was no change in IFP neither in tumors nor in muscle. The results of our preliminary study on the effect of hydralazine on IFP in SAF tumor model is in accordance to previously reported studies. The decrease in tumor IFP was only observed in tumors, but not in muscle and surrounding subcutis. Conclusion. Hydralazine is a vasodilator which is capable of decreasing tumor IFP, reproducibly and with favorably long lasting dynamics.
Keywords: sarcoma, experimental drug therapy, hydralazine, extracellular space, interstitial fluid pressure, manometry
Published in DiRROS: 23.01.2024; Views: 213; Downloads: 55
 Full text (497,71 KB) |
32. |
33. |
34. Study of blood perfusion with patent blue staining method in LPB fibrosarcoma tumors in immuno-competent and immuno-deficient mice after electrotherapy by direct currentTomaž Jarm, Dong Jian An, Jean Belehradek, Lluis M. Mir, Gregor Serša, Maja Čemažar, Tadej Kotnik, Jani Pušenjak, Damijan Miklavčič, 1997, original scientific article Published in DiRROS: 16.01.2024; Views: 178; Downloads: 41
Full text (344,22 KB) |
35. Electrochemotherapy with bleomycin : The first clinical experience in malignant melanoma patientsZvonimir Rudolf, Borut Štabuc, Maja Čemažar, Damijan Miklavčič, Lojze Vodovnik, Gregor Serša, 1995, original scientific article Keywords: melanoma therapy, bleomycin, electric stimulation therapy
Published in DiRROS: 15.01.2024; Views: 216; Downloads: 48
Full text (418,42 KB) |
36. Improved therapeutic effect of electrochemotherapy with cisplatin by intratumoral drug administration and changing of electrode orientation for electropermeabilization on EAT tumor model in miceMaja Čemažar, Damijan Miklavčič, Lojze Vodovnik, Tomaž Jarm, Zvonimir Rudolf, Borut Štabuc, Tanja Čufer, Gregor Serša, 1995, original scientific article Keywords: neoplasmas, experimental therapy, cisplatin, electric stimulation therapy, cell membrane permeability
Published in DiRROS: 15.01.2024; Views: 181; Downloads: 50
Full text (393,12 KB) |
37. |
38. Presejalni program zgodnjega odkrivanja raka dojkDamijan Škrk, 2004, published scientific conference contribution Abstract: Izhodišča. Presejalni program zgodnjega odkrivanja raka dojk je s stališča varstva pred ionizirajačimi sevanji upravičen, če je pričakovana skupna koristvečja od tveganja oz. škode za zdravje. Izvajanje postopkov optimizacijezagotavlja, da se posegi izvajajo z uporabo posegom prilagojene radiološke in druge potrebne opreme ter po pisnih postopkih. Zaključki. Posebno pozornost je potrebno posvetiti zagotavljanju in preverjanju kakovostimamografije vključno z oceno obsevanosti preiskovane osebe. Pri oblikovanju srnernic ob uvajanju nacionalnega presejalnega programa zgodnjega odkrivanja raka dojk v Sloveniji smo uporabili podatke podobnega programa v Veliki Britaniji. Kaže se tudi potreba po prerazporeditvi števila posegov med pokrajinami oziroma aparati ter razmislek o morebitni dodatni mobilni mamografski napravi.
Published in DiRROS: 01.12.2023; Views: 186; Downloads: 59
Full text (476,60 KB) |
39. Zakon o merilih kakovosti pri mamografijiDamijan Škrk, 2001, published scientific conference contribution Abstract: V Združenih državah Amerike so oktobra 1992 sprejeli Zakon o merilih kakovostipri mamografiji. Zakon, ki je postavil temelje kakovostni mamografskidejavnosti, predpisuje postopke, s katerimi ustanove skrbijo za skladnost z merili kakovosti, in način pridobitve dovoljenja za opravljanje mamografske dejavnosti. Ministrstvo za zdravje, ki je pristojno za izvajanje določil zakona, je pooblastilo Urad za hrano in zdravila za implementacijo zakona, izdajanje soglasij za delo pooblaščenih teles, ki preverjajo kakovost mamografske dejavnosti in izdajo dovoljenj za opravljanje mamografske dejavnosti. Članek želi predstaviti obseg in cilje Zakona o merilih kakovosti pri mamografiji, ki bi jih lahko uporabljali kot vodilo pri pripravi mamografskih meril kakovosti v Sloveniji.
Published in DiRROS: 30.11.2023; Views: 223; Downloads: 58
Full text (304,73 KB) |
40. Elektrokemoterapija malignega melanomaGregor Serša, Borut Štabuc, Tanja Čufer, Boris Jančar, Damijan Miklavčič, Maja Čemažar, Zvonimir Rudolf, 1999, published scientific conference contribution Keywords: melanom, zdravljenje, bleomicin, cisplatin, električna stimulacija, elektrokemoterapija, elektroporacija, melanoma therapy, bleomycin, cisplatin, electric stimulation therapy, electrochemotherapy, electroporation
Published in DiRROS: 27.11.2023; Views: 201; Downloads: 67
Full text (617,96 KB) |
